TRIPLE NEGATIVE BREAST CANCER (TNBC)

This is the first human study testing the safety of an experimental drug called AB598 in people with advanced cancers. The trial will enroll 40 participants with various cancers including lung, stomach, bladder, and breast cancer to determine safe dosage levels and monitor side e…

This early-stage trial is testing a new oral medication called BBI-355, both alone and in combination with other drugs, for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to find safe doses and see if the treatment can shrink…

This study is testing whether adding a new, experimental drug called onvansertib to a standard chemotherapy (paclitaxel) is safe and effective for people with triple-negative breast cancer that has spread. The first part finds the safest dose, and the second part checks if the co…

This study is testing a combination of two chemotherapy drugs (liposomal doxorubicin and carboplatin) given after surgery for early-stage triple-negative breast cancer (TNBC). The main goal is to see if this treatment can lower the chance of the cancer returning. Researchers will…

This early-stage study is testing a new drug called RNDO-564, both by itself and combined with an existing immunotherapy (pembrolizumab), in adults with advanced cancers that have stopped responding to standard treatments. The main goals are to find safe doses and see how the bod…

This study is testing whether specific exercise programs can help women with early triple-negative breast cancer recover better after surgery. Researchers want to see if exercise can improve the body's ability to use energy efficiently, maintain muscle, and enhance overall well-b…